Claims
- 1. A cytokine prepared by inactivating said cytokine by treatment with an aldehyde, whereby said cytokine becomes biologically inactive.
- 2. The cytokine according to claim 1, wherein said cytokine is a human cytokine.
- 3. The cytokine according to claim 1, wherein said cytokine is a murine cytokine.
- 4. The cytokine according to claim 1, wherein said cytokine is selected from the group consisting of interferon-α, interferon-β, interferon-γ, interleukin-2, interleukin-4, interleukin-5, interleukin-6, tumor necrosis factor α, tumor necrosis factor β, and transforming growth factor-β.
- 5. The cytokine according to claim 1, wherein said cytokine is selected from the group consisting of interferon-α, interferon-β, and transforming growth factor β.
- 6. The cytokine according to claim 5, wherein said cytokine is interferon-α.
- 7. The cytokine according to claim 5, wherein said cytokine is interferon-β.
- 8. The cytokine according to claim 5, wherein said cytokine is transforming growth factor β.
- 9. An immunizing composition for reducing the load of overproduced native cytokine in a condition associated with overproduction of a specific native cytokine, comprising an immunizing effective amount of an inactive cytokine according to claim 1 and a pharmaceutically acceptable immunizing carrier, wherein said inactive cytokine is a molecule which is sufficiently structurally related to said native cytokine to generate an immune response which cross-reacts with said native cytokine, but which otherwise lacks the biological activity of the native cytokine in the subject.
- 10. The immunizing composition according to claim 9, wherein said native cytokine is selected from the group consisting of interferon-α, interferon-β, interferon-γ, interleukin-2, interleukin-4, interleukin-5, interleukin-6, tumor necrosis factor a, tumor necrosis factor ⊕, and transforming growth factor-β.
- 11. The immunizing composition according to claim 9, wherein said native cytokine is selected from the group consisting of interferon-α, interferon-β, and transforming growth factor β.
Priority Claims (1)
Number |
Date |
Country |
Kind |
91 07399 |
Jun 1991 |
FR |
|
Parent Case Info
This is a continuation of copending parent application Ser. No. 08/167,867, filed Jun. 27, 1994, now U.S. Pat. No. 6,093,405.
Nucleic Acid Research, Vol 11, No. 3, February 1993, Arlington, Va., pages 555-573 describes native molecules of murine interferon α 1 and α 2. GB-A-2 157 697 describes native molecules of bovine interferon α. WO-A-8 805 783 describes peptides homologous to a fragment of the retroviral molecule of murine virus MLV p15E, these peptides being endowed with suppressive properties, also the use of these peptides as immunizing agents against a retroviral infection or on the contrary to induce an immunosuppression.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
4264587 |
Pedersen |
Apr 1981 |
A |
Foreign Referenced Citations (1)
Number |
Date |
Country |
0387095 |
Sep 1990 |
EP |
Continuations (1)
|
Number |
Date |
Country |
Parent |
08/167867 |
Jun 1994 |
US |
Child |
09/317993 |
|
US |